Alkermes Receives Refusal to File Letter From FDA for ALKS 5461

DUBLIN, April 2, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it received a Refusal to File letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ALKS 5461, a once-daily, oral...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news